Two dogs in New Jersey have tested positive for a drug-resistant strain of bacteria connected to a fatal outbreak related to eyedrops last year, as reported by a CDC investigator. The bacteria identified, known as carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa, is genetically linked to the germs that affected 81 individuals across 18 states, resulting in 14 cases of vision loss and four deaths. This alarming development was disclosed by Emma Price during a conference held by the CDC’s Epidemic Intelligence Service.
Health experts are expressing concern over the presence of germs producing carbapenemase due to their ability to break down carbapenem antibiotics, which are typically reserved for drug-resistant infections. There is apprehension that the resistance genes could potentially transfer to other pathogens, heightening the risk of antibiotic resistance. Following the discovery of unusual signs of resistance in the dogs’ swabs at a Pennsylvania laboratory, the genetic sequence of the strain was uploaded to a national database, prompting investigations by the CDC and state health authorities.
In response to the contamination, the FDA issued warnings to consumers about the affected eyedrops last fall and requested recalls. The introduction of this bacteria into the US from artificial tears raises concerns about the potential spread of resistance, posing a significant public health risk. The collaboration between various health agencies highlights the importance of vigilance in preventing the dissemination of drug-resistant strains in both humans and animals.
The identification of a drug-resistant bacterial strain in dogs emphasizes the interconnectedness of public health concerns between humans and their pets. The investigation into the source of the contamination underscores the need for stringent monitoring and regulation of pharmaceutical products to safeguard against potential outbreaks. The implications of this discovery extend beyond the immediate cases in pets, serving as a reminder of the ongoing challenges posed by antibiotic resistance in healthcare settings and the importance of proactive measures to address these threats.